MTNB

Matinas BioPharma Holdings, Inc.

NYSEHealthcarePHARMACEUTICAL PREPARATIONS

Insider activity for last month from Oct 16 to Nov 16.

How these metrics are calculated

Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Total buying$00 buys
Total selling$00 sales
Net open-market$0Buying minus selling
Active insiders3Distinct reporting owners

MTNB transaction history

Newest filings · 20 transactions per page

Latest insider transactions

Form 4 filings from last month.
Newest company filings
InsiderActivityDisclosed valueFiled (ET)
Murphy Keith
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Amended
Form 4/A: an amendment to a filing.
Derivative securitySEC filing ↗
$0View disclosure →
Neugeboren Edward
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Amended
Form 4/A: an amendment to a filing.
Derivative securitySEC filing ↗
$0View disclosure →
D An Evelyn
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Amended
Form 4/A: an amendment to a filing.
Derivative securitySEC filing ↗
$0View disclosure →
Murphy Keith
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
D An Evelyn
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
Neugeboren Edward
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →

Insider activity report

Calendar-month buckets within the selected date range

Latest filing: Nov 9, 2026

Open-market transaction mix · 0 transactions in the selected period

Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.

View exact monthly counts and disclosed values
Monthly activity within the selected period; unknown values remain unknown.
MonthBuysSellsAwards (A)Buy valueSell valueNet P/S value
Oct 2026000$0$0$0
Nov 2026006$0$0$0

Distinct insiders active

Reporting-owner CIKs by month · peak Nov 2026 (3)
Oct 2026: 0 insidersNov 2026: 3 insiders
Oct 2026Nov 2026
3distinct insiders in selected period
Largest insider activity
By absolute net disclosed value · current transaction page
3 insiders
  • MK
    Murphy KeithDIR · 0 buys · 0 sales · 2 awards (A)
    $0last Nov 9
  • NE
    Neugeboren EdwardDIR · 0 buys · 0 sales · 2 awards (A)
    $0last Nov 9
  • DE
    D An EvelynDIR · 0 buys · 0 sales · 2 awards (A)
    $0last Nov 9
Filing, role and holdings details

Filing-only signals

Deterministic matches in the selected period

Recent filing activity
Most recent 6 transactions on this page · color = transaction code

Filing detail checks

Secondary metrics for the selected period
Largest buy—
Largest sale—
10b5-1 detected0
Amended rows3

Transaction codes

By Form 4 transaction code in selected period
6transactionstxns
  • A · Grants / awards · dominant6 · 100%

Activity by reported role

A joint filing can contribute to multiple roles
Director6

Reported Holdings After

Separated by insider, security, and ownership type

Neugeboren EdwardStock Option (right to Buy) · Direct
5.00k5.00kNov 6, 2026Nov 6, 2026
5,000Nov 6, 2026
D An EvelynStock Option (right to Buy) · Direct
5.00k5.00kNov 6, 2026Nov 6, 2026
5,000Nov 6, 2026
Murphy KeithStock Option (right to Buy) · Direct
5.00k5.00kNov 6, 2026Nov 6, 2026
5,000Nov 6, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells red
2 active days
Oct 16 → Nov 16
LessMore

Matinas BioPharma Holdings, Inc. Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at Matinas BioPharma Holdings, Inc.?

Murphy Keith, NEUGEBOREN EDWARD, D An Evelyn.

When was the latest reported open-market purchase?

No code-P purchase is available for this period.

When was the latest reported open-market sale?

No code-S sale is available for this period.

What is the recent purchase and sale balance?

No code-P purchases or code-S sales were reported in the selected period.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.